Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan hydrochloride
Drug ID BADD_D01377
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status approved
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D08173
MeSH ID D008558
PubChem ID 9927978
TTD Drug ID D00FGO
NDC Product Code 59651-684; 63552-076; 17337-0304; 68554-0087; 76055-0011; 43598-392; 67457-215; 45963-686; 70860-214; 71288-112; 71288-132; 76339-111; 54288-109; 70700-278; 62207-978; 43598-027; 72266-128; 46439-8735; 63323-760; 67457-195; 68083-259; 59981-016; 72611-779; 82920-020
UNII 1VXP4V453T
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H19Cl3N2O2
CAS Registry Number 3223-07-2
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Blood urea increased13.13.01.006--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.001--
Death08.04.01.001--
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Diarrhoea07.02.01.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Feeling hot08.01.09.009--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Hepatitis09.01.07.004--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Skin necrosis23.03.03.011--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Urticaria23.04.02.001; 10.01.06.001--
The 1th Page    1 2    Next   Last    Total 2 Pages